THE EUROPEAN MEDICINES AGENCY
- Country
- Netherlands
- Type
- Beneficiary
- Website
- www.ema.europa.eu/
- Grants received
- 16
Funding record
- 16 grants on record
- €2,119,141.25 awarded in total
- 2009–2025 years covered
This total adds up only the grants our sources publish. It is not the total funding this organisation has received.
Programmes
10 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations funded alongside this one on two or more projects. Sharing a single project does not count. Some projects have as many as 195 participants, and appearing on the same list once is not a working relationship.
- JANSSEN PHARMACEUTICA NV
- ACADEMISCH ZIEKENHUIS GRONINGEN
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN
- NOVARTIS PHARMA AG
- SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
- AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS
- BAYER AKTIENGESELLSCHAFT
Calls from this organisation
No published calls from this organisation.
Grants received
- Breakthrough Regulatory Innovation and Development throuGh sandbox Environments
- Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases
- European Partnership Animal health and Welfare
- Exploiting fundamental insights of m6A methylation on CD8 T cell differentiation and function to boost medicinal T cell products
- Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
- Prioritisation and Risk Evaluation of Medicines in the EnviRonment
- Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
- Strengthening training of academia in regulatory sciences and supporting regulatory scientific advice (STARS)
- Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890
- Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection
- Recognising Adverse Drug Reactions
- Incorporating real-life clinical data into drug development
- Accelerated Development of Vaccine benefit-risk Collaboration in Europe
- Global Research in Paediatrics
- European programme in Pharmacovigilance and Pharmacoepidemiology
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
We collected this from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.